Earnings jump puts Krystal Biotech stock in focus

Krystal Biotech (KRYS) is drawing attention after reporting first quarter net income of US$55.93 million, with both basic and diluted earnings per share above figures reported a year earlier.

The stock's 1 month share price return of 11.70% and year to date share price return of 24.05% point to building momentum, while the 1 year total shareholder return of 134.53% highlights how strongly long term holders have already been rewarded.

If Krystal's recent move has you looking across healthcare, this is a helpful moment to scan other genetic and biotech opportunities through our focused screener, including 32 healthcare AI stocks

With Krystal Biotech now profitable and trading around US$306, plus an analyst price target close to US$323 and a wide gap versus some intrinsic value estimates, should you see a mispriced opportunity here, or has the market already factored in future growth?

Most Popular Narrative: 2.8% Undervalued

The most followed narrative pegs Krystal Biotech's fair value at about $315, slightly above the last close of $306.29, and builds that view on ambitious growth and profitability assumptions.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product.

Want to see what kind of revenue ramp, margin profile, and future earnings multiple are baked into that fair value? The narrative leans heavily on aggressive growth, rising profitability, and a richer profit multiple than the broader biotech sector, all stitched together using a specific discount rate and detailed 2029 forecasts.

Result: Fair Value of $315 (UNDERVALUED)

However, the story can change quickly if VYJUVEK demand or international reimbursement decisions disappoint, or if KB707 and other late stage trials encounter clinical or regulatory setbacks.

Another View: Market Multiple Sends a Caution Flag

That 2.8% undervaluation story sits against a very different signal from the market multiple. Krystal Biotech trades on a P/E of 40.1x, compared with 17.2x for the US Biotechs industry, 8.3x for peers, and a fair ratio estimate of 28.1x, which points to richer pricing and higher valuation risk if expectations slip.

For anyone weighing these cross currents, it helps to see how current pricing compares with that fair ratio and where the gaps are most pronounced, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment this mixed, it makes sense to look past headlines and dig into the details yourself so you can move quickly if your view shifts. To see what has investors optimistic right now, check out the 3 key rewards

Looking for more investment ideas?

If Krystal Biotech has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to surface fresh ideas before others spot them.

• Target potential bargains by reviewing companies highlighted in the 51 high quality undervalued stocks and see which stocks align with your return and risk appetite.
• Protect your downside by focusing on companies in the 66 resilient stocks with low risk scores that combine resilient fundamentals with more measured volatility.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems and spotting quality businesses that many investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.